Antitumor activity of intravesical Vinorelbine in ortothopic murine transitional cell carcinoma of bladder

BONFIL, RD, RUSSO, DM, SCHMILOVICH, AJ Y GARCÍA PALAZZO, IE.

Washington DC, USA

Congreso; 87thAnnual Meeting of the American Association for Cancer Research.; 1996

American Association for Cancer Research

#2435 Antitumor activity of intravesical Vinorelbine in orthotopic murine transitional carcinoma of the bladder. Bonfil, R.D., Russo, D.M., Schmilovich A.J y García-Palazzo, I.E. Lab. Fundación de Investigación del Cáncer, CEFYBO, and Lab. Rontag, Buenos Aires, Argentina. Department of Patology, Temple University, Philadelphia, USA. We have previously reported the antiproliferative and anti-invasive effects of Vinorelbine (VNR) in MB-49, a murine transitional cell carcinoma of the bladder (TCC) (Proc. AACR 36: 350 # 2083, 1995). To ascertain its antitumor activity against TCC in an in vivo setting, C57/Bl6J female mice were intravesically implanted with 5 x 10 4 MB-49 cells and treated locally on day 0 with 0.1 ml VNR (2 mg/ml). Sixteen days later tumor incidence was significantly lower in VNR-treated mice (48% n=23) than controls (84% n=19) (p=0, 02 Test x 2). Intravesical tumor volume was also significantly smaller in treated mice respect to controls (Median [range]: 0 [0-61,8] mm 3 vs.  33,5 [0-179,7] mm 3 respectively, p=0,0005U-Mann Whitney test ).The survival duration of the animals treated with  VNR was 54,2  ±8,5 days , and was significantly greater (p=0,0002, Student´s  t test) than with untreated controls (17,8  ±0,5 days). Many VNR-treated mice remained tumor free at day 65, when terminated the survival experiment, as evidenced at necropsy by histopathological studies. The results obtained suggest a potential use of VNR as a local treatment for survival TCC following transurethral bladder tumor resection to prevent recurrence or retard tumor growth